In our latest podcast we discuss urothelial carcinoma and the latest advances in treating with antibody drug conjugates (ADCs), as a new therapeutic option. Dr Tony Michele, Medical Oncologist from Adelaide Oncology and Haematology, part of the Genesiscare Group, and PCPA Board member is joined by Dr Elizabeth Liow, Medical Oncologist at Monash in Melbourne and Dr Laurence Krieger, Medical Oncologist at Genesis Care North Shore Hub in Sydney. Our podcasters deep experience in managing these patients is invaluable in this transforming field of expertise.

https://www.pcpa.org.au/

In this PCPA Podcast Dr Ian Irving, PCPA Board Member, Haematologist and Chief Medical Officer at ICON Group, discusses CAR T-cell therapy, a transformative approach reshaping the landscape of haematologic malignancies. CAR T-cell therapy leverages a patient's own immune system to target and eradicate cancer cells with remarkable precision. Throughout this episode, we delve into the mechanisms of action, clinical trial data, and practical considerations for integrating CAR T-cell therapy into your practice. Ian is joined by Associate Professor Mary Ann Anderson, Haematologist from the Peter MacCallum Cancer Centre in Melbourne and Dr Allison Barraclough, Haematologist from the Fiona Stanley Hospital in Perth.

In this PCPA Podcast we focus on Leadership Stories: Women in Oncology Research, launched on International Women’s Day 2024. Professor Fran Boyle, Medical Oncologists and Supportive care Physician from the Mater Hospital in Sydney discusses the unique challenges and opportunities with Professor Victoria Atkinson from Greenslopes Private Hospital and the Princess Alexandra Hospital in Brisbane and also Dr Amy Davies, Medical Oncologist and Research Scientist from Victoria.

We tackle: Is it necessary to go overseas to progress your career? Can you do great research in the private sector? What are the special qualities and strengths women bring to cancer care? This episode is a powerful tribute to the remarkable women who are shaping the future of cancer research and making a significant impact on the lives of thousands of cancer patients. It's a reminder of the importance of diversity and inclusion in scientific research and the crucial role women play in driving innovation and progress.

In this PCPA podcast we discuss The What, When, Why and How of IDH Mutations in Cancer? The discussion covers the understanding of IDH mutations in cancer, a completely new enzyme driving cancer in both solid tumours and in haematology. Experts are on hand to cover the nuances in molecular testing and review current and future therapies and trends in these patient populations.

Dr Shehara Mendis, Medical Oncologist from Cabrini Hospital in Melbourne chairs this discussion with Dr Michael Rodriguez, Consultant Neuropathologist, St Vincent's Hospital and POW Hospital Sydney; Douglass Hanly Moir Pathology and Associate Professor Daniel Thomas, a Clinical Haematologist and Cancer Scientist from the University of Adelaide.

In this PCPA podcast we discuss “Most Patients With Cancer are Older - How Does this Impact their Care?” The conversation explores this specialised field which focuses on the care of older adults with cancer. Since more than 50% of patients will be over 65 years of age in the next few years and as an oncologist treating older patients with cancer, it's crucial to understand the unique challenges and considerations involved in their care .

A/Professor Christopher Steer , medical oncologist from Albury/Wodonga and President of the Private Cancer Physicians of Australia is joined by Dr Etienne Brain, MD, PhD, senior medical oncologist at Institut Curie, in Saint-Cloud, France, who was honoured with the 2022 B.J. Kennedy Geriatric Oncology Award for his career-long contributions to advancing clinical research in breast cancer in older populations.

Dr Cameron McLaren, Medical Oncologists and PCPA Board Member from Victoria is joined by Laurie Draper, a voluntary assisted dying care navigator from the State-wide Care Service in Melbourne and Dr Hilda High Medical Oncologist specialising in Cancer Genetics from Sydney. In this Private Cancer Physician of Australia podcast they discuss voluntary assisted dying and what you need to know as a health care professional to manage the change in care. With the impending changes around the country regarding voluntary assisted dying Dr Hilda High asks pertinent questions for health professionals to Cam and Laurie to draw on their experience with their program in Victoria.

https://www.gogentleaustralia.org.au/conference_2023 - VAD National Conference 2023

https://cesphn.org.au/news/voluntary-dying-conference - NSW VAD Implementation Conference 2023

Molecular profiling plays a crucial role in optimizing cancer care by enabling personalized treatment decisions, improving treatment outcomes, and offering potential avenues for targeted therapies and clinical trial participation. In this PCPA Podcast, Professor Desmond Yip, PCPA Secretary and Treasurer and Senior Staff Specialist in Medical Oncology at the Canberra Hospital is joined by Professor Lorraine Chantrill, Senior Staff Specialist Medical Oncologist and Head of Service for Medical Oncology across the Illawarra Shoalhaven Local Health District (ISLHD), and Area Clinical Director of Clinical Trials and also Dr Vivek Rathi, Director of Operations, Group Medical Director, Group Molecular Pathologist at LifeStrands Genomics. In this podcast, they discuss precision medicine for Australian patients with cancer, current genetic pathology and actionable targets. We look to the future of comprehensive genomic profiling (CGP) and how to make this a clinical solution for all.

The PCPA is a dynamic, not-for-profit Oncology specialist organisation that aims to improve the care of cancer patients in the private health system, believing that cancer care should be the best it can be for our patients, their families and our members who are entrusted to care for them.

The Private Cancer Physician’s Podcast series on Managing Patients with Cancer is pleased to release its new podcast: Antibody-Drug Conjugates: Transforming Breast Cancer Treatment

In this podcast, we discuss antibody-drug conjugates (ADCs) and the transformative role they are playing in the fight against metastatic breast cancer. ADCs are “smart bombs” that provide a new construct to treat metastatic breast cancer, with higher efficacy and less off target toxicities. Dr Richard de Boer, Medical Oncologist from the Peter MacCallum Cancer Centre is joined by Professor Hope Rugo, Director, Breast Oncology and Clinical Trials Education and Medical Director of Cancer Infusion Services, UCSF as well as Dr Belinda Yeo, Medical Oncologist from the Austin Hospital in Melbourne, Australia, and Clinician Scientist from the Olivia Newton-John Cancer Research Institute.

Produced by ScienceToLife